Active Ingredient(s):Tafasitamab-cxix FDA Approved: * July 31, 2020 Pharm Company: *MORPHOSYS US INC Category:Cancer
Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swellin...
* May have multiple approval dates, manufacturers, or labelers.